| Abstrakt: |
A preprint abstract from biorxiv.org discusses the potential use of a synthetic nonviral gene delivery platform to express a bacterial enzyme called RAS/RAP1-specific endopeptidase (RRSP) in pancreatic cancer cells. The study suggests that this strategy could lead to the degradation of RAS proteins, which are often abnormal in cancer cells and contribute to tumor growth. The researchers found that the mRNA-loaded synthetic nanocarrier successfully delivered the RRSP gene to human and mouse pancreatic cells, resulting in reduced tumor size and decreased RAS signaling. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article] |
